Menu
Search
|

Menu

Close
X

Achaogen Inc AKAO.OQ (NASDAQ Stock Exchange Global Market)

10.99 USD
+0.17 (+1.57%)
As of Feb 24
chart
Previous Close 10.82
Open 10.87
Volume 172,224
3m Avg Volume 290,056
Today’s High 11.04
Today’s Low 10.74
52 Week High 27.78
52 Week Low 9.83
Shares Outstanding (mil) 42.23
Market Capitalization (mil) 644.48
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 12 analysts

KEY STATS

Revenue (mm, USD)
FY17
9
FY16
42
FY15
26
EPS (USD)
FY17
-2.323
FY16
-2.985
FY15
-1.488
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
18.15
5.77
Price to Book (MRQ)
vs sector
3.61
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
20.00
16.52
LT Debt to Equity (MRQ)
vs sector
14.16
12.22
Return on Investment (TTM)
vs sector
-66.68
14.43
Return on Equity (TTM)
vs sector
-92.67
16.13

EXECUTIVE LEADERSHIP

Bryan Roberts
Independent Chairman of the Board, Since 2009
Salary: --
Bonus: --
Kenneth Hillan
President, President - R&D and Director, Since 2018
Salary: $435,000.00
Bonus: --
Blake Wise
Chief Executive Officer, Director, Since 2018
Salary: $410,000.00
Bonus: --
Tobin Schilke
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Since 2016
Salary: --
Bonus: --
Lee Swem
Senior Vice President, Chief Scientific Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

7000 Shoreline Ct Ste 371
SOUTH SAN FRANCISCO   CA   94080-7603

Phone: +1650.8003636

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

SPONSORED STORIES